Fig. 1From: Delivery strategies of cancer immunotherapy: recent advances and future perspectivesTimeline of FDA-approved cancer immunotherapies. FDA Food and Drug Administration, IFN interferon, IL interleukin, mAb monoclonal antibody, CTLA-4 cytotoxic T lymphocyte antigen 4, PD-1 programmed cell death 1, PD-L1 PD-1 ligand 1, CAR chimeric antigen receptorBack to article page